Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms the mister hyde face of a safe drug

Cancer

Volumn 118, Issue 2, 2012, Pages 404-409

  Latagliata, Roberto ^a   Spadea, Antonio ^b   Cedrone, Michele ^c   Di Giandomenico, Jonny ^d,k   De Muro, Marianna ^e   Villivà, Nicoletta ^f   Breccia, Massimo ^a   Anaclerico, Barbara ^c   Porrini, Raffaele ^g   Spirito, Francesca ^h   Rago, Angela ⁱ   Avvisati, Giuseppe ^e   Alimena, Giuliana ^a   Montanaro, Marco ^j   Andriani, Alessandro ^f   Volpicelli, Paola ^a   Ferretti, Antonietta ^a   Mazzucconi, Maria Gabriella ^a   Annino, Luciana ^c   Felici, Stefano ^f   Montefusco, Enrico ^g   Majolino, Ignazio ^h   Trapè, Giulio ^j   Pessina, Gloria ^j   Cotroneo, Ettore ^d   Lo Coco, Francesco ^d   Abruzzese, Elisabetta ^l   Cimino, Giuseppe ⁱ   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e University Biomedical Campus ^*  (Italy)

^f NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

ⁱ SANTA MARIA GORETTI HOSPITAL   (Italy)

^j BELCOLLE HOSPITAL   (Italy)

^k IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^l S EUGENIO HOSPITAL   (Italy)

more..

Author keywords

Hydroxyurea; Mucocutaneous toxicity; Myeloproliferative neoplasms; Partial resolution

Indexed keywords

HYDROXYUREA;

ADULT; AGED; APHTHOUS ULCER; ARTICLE; BONE MARROW CANCER; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS TOXICITY; NONULCERATIVE SKIN TOXICITY; PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SKIN TOXICITY; ULCERATIVE SKIN TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; SKIN DISEASES; SKIN ULCER; WITHHOLDING TREATMENT;

EID: 84855495332     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26194     Document Type: Article

References (24)

1. Dresler WF, Stein R. Ueber den Hydroxylharnstoff. Justus Liebig's Ann Chem Pharm. 1869;150:242-252.
2. Rosenthal F. Ueber die Beziehungen von schwersten Blutgiften zu Abbauprodukten des Eiweisses: Ein Beitrag zum Enstehungsmechanismus der perniziosen Anamie. Klin Wochenschr. 1928;7:972-977.
3. Kovacic P. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011;76:24-31
4. Tarnowski GS, Stock CC. Chemotherapy studies on the RC and S 790 mouse mammary carcinomas. Cancer Res. 1958;18(8 pt 2):1-48.
5. Brockman RW, Shaddix S, Laster WR, Schabel FM Jr. Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole. Cancer Res. 1970;30:2358-2368.
6. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109:5104-5111. (Pubitemid 46890524)
7. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232. (Pubitemid 38796497)
8. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009;113:5394-5400.
9. Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori. 1986;72:317-321. (Pubitemid 17190693)
10. Radaelli F, Calori R, Faccini P, Maiolo AT. Early cutaneous lesions secondary to hydroxyurea therapy. Am J Hematol. 1998;58:82-83. (Pubitemid 28213566)
11. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea- induced leg ulceration in 14 patients. Ann Intern Med. 1998;128:29-32. (Pubitemid 28016715)
12. Stagno F, Guglielmo P, Consoli U, Fiumara P, Russo M, Giustolisi R. Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor. Blood. 1999;94:1479-1480. (Pubitemid 29380431)
13. Tarumoto T, Imagawa S, Hotta T, et al. A case of bilateral heel ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia. Jpn J Clin Oncol. 2000;30:159-162. (Pubitemid 30335841)
14. Sastre JL, Bravo A, Tembras S, Gomez R, Ulibarrena C. Leg ulcers associated with hydroxyurea therapy. Haematologica. 2003;88:EIM01.
15. Lankipalli R, Konkle B, Mohler ER 3rd. An unusual case of toe ulceration. Vasc Med. 2006;11:35-37.
16. Romanelli M, Dini V, Romanelli P. Hydroxyurea-induced leg ulcers treated with a protease-modulating matrix. Arch Dermatol. 2007;143:1310-1313. (Pubitemid 47607680)
17. Hwang SW, Hong SK, Kim SH, Seo JK, Lee D, Sung HS. A hydroxyurea-induced leg ulcer. Ann Dermatol. 2009;21:39-41.
18. Martorell-Calatayud A, Requena C, Nagore-Enguidanos E, Guillen-Barona C. Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea [in Spanish]. Actas Dermosifiliogr. 2009;100:804-807.
19. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377. (Pubitemid 27473405)
20. Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol. 1999;135:818-820. (Pubitemid 29330806)
21. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005;90:261-262. (Pubitemid 40293293)
22. Ruzzon E, Randi ML, Tezza F, Luzzatto G, Scandellari R, Fabris F. Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. Aging Clin Exp Res. 2006;18:187-190. (Pubitemid 44083736)
23. Harrison CN, Campbell PJ, Buck G, et al; United Kingdom Medical Research Council Primary Thrombocythemia1 Study. Hydroxyurea compared with anagrelide in high - risk essential thrombocythemia. N Engl J Med. 2005;353: 33-45.
24. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961-963.